Dana-Farber Cancer Institute

Geoffrey M. Cooper Dana-Farber Cancer Institute Boston, Massachusetts... 

Harvard Medical School, Dana-Farber Cancer Institute, Boston, Mass., USA... 

Two studies have reported a positive association between MTHFR polymorphisms and pediatric ALL relapse risk (Table 1). The first study by Krajinovic et al. evaluated 201 children with ALL treated with methotrexate as per Dana Farber Cancer Institute (DFCl) protocols 87-01, 91-01, or 95-01. Thus, the study demonstrated that the MHFR T677A1298 haplotype was associated with a decreased disease-free survival in multivariate analysis. When children with either the MTHFR T677A1298 haplotype or the MTHFDl A195 8 variant also had a triple-repeat thymidylate synthase polymorphism, the correlation with decreased EFS was also significant (5). However, neither of the MTHFR polymorphisms alone was significantly associated with altered survival. These analyses did not include toxicity risks. 

CBR Institute for Biomedical Research, Department of Pathology, Harvard Medical School, Boston, Massachusetts 02115 Dana-Farber Cancer Institute, Departments of Pediatrics, Biological Chemistry and Molecular Pharmacology, Harvard Medical School,... 

Arthur Pardee, later. Professor of Biological Chemistry and Molecular Pharmacology at Harvard, and did outstanding research at Dana-Farber Cancer Institute. 

Dana-Farber Cancer Institute D810 44 Binney Street, Boston, MA 02115... 

Verzosa MS, Aur RJA, Simone JV, et al Five years after central nervous system irradiation of children with leukemia. Int J Radiat Oncol Biol Phys 1 209-215, 1976 Waber DP, Shapiro BL, Carpentieri SC, et al Excellent therapeutic efficacy and minimal late neurotoxicity in children treated with 18 grays of cranial radiation therapy for high-risk acute lymphoblastic leukemia a 7-year follow-up study of the Dana-Farber Cancer Institute Consortium Protocol 87-01. Cancer 92 15-22, 2001 Wachowski TJ, Chenault H Degenerative effects of large doses of roentgen rays on the human brain. Radiology 45 227-246, 1945... 

Financial support from the NIH Cancer Institute (R21 CAl 1949-01) is acknowledged. We also acknowledge Drs. Daniel Cramer, Samuel Mok and Brian Liu from Brigham and Women s Hospital and Dr. Miron Alexander from Dana-Farber cancer Institute for their encouraging discussion during the manuscript preparation. 

The Patient and Family Advisory Council at Dana-Farber Cancer Institute was created in the late 1990s with fifteen patients and family members who agreed to one-year terms renewable for up to three years. Several members participated and shared voting privileges. Members made the commitment to attend one meeting per month and to participate in the work of at least one subcommittee, for a total commitment of fewer than ten hours per month. 

First, we make a general acknowledgment to major contributors to the field of patient safety whose work we have drawn on for this book. Among them are James Reason, Karl Weick, Jens Rasmussen, Richard Cook, David Woods, and Karlene Roberts. Special thanks to Lucian Leape for writing the Foreword he has been not only a pioneer in the field but also a mentor. Don Berwick, president of the Center for Healthcare Improvement, and Jim Conway, chief operating officer of the Dana-Farber Cancer Institute, both in Boston, have made substantial contributions through their work, which appears in this book. 

The contributions of the following reviewers vastly improved the content of the book Roger Rezar, M.D., Luther-Midelfort Hospital, Eau Claire, Wisconsin Della Lin, M.D., the Queen s Medical Center, Honolulu, Hawaii Richard Cook, M.D., Cognitive Technologies Laboratories, University of Chicago Peter Provonost, M.D., Ph.D., critical care medicine, Johns Hopkins University Jim Conway, Dana-Farber Cancer Institute Linda Connell, M.A., R.N., the NASA Ames Research Center and Anne-Claire France, Ph.D., the Center for Healthcare Improvement, Memorial Hermann Healthcare System, Houston. 

Barrett J. Rollins, md, phd The Dana-Farber Cancer Institute and the Department of Medicine, Harvard Medical School, Boston, MA... 

Vrooman LM, Neuberg DS, Stevenson KE, AsseUn BL, Athale UH, Clavell L, et al. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia a report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Cancer 2011 47(9) 1373-9. 

---